WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

US tech giants rebounded collectively on Monday. Apple rose 1%, Microsoft rose 0.88%, Amazon rose 1.89%, NVIDIA rose 1.92%, Alphabet (Google-A) rose 1.20%, Tesla rose 1.17%, Meta rose 2.9%, and ...

Solar stocks slid in off-hours trading after Senate Republicans kept in a full phase-out of solar and wind energy tax credits in [President Trump's budget bill]( ...